Global Benidipine Market Size, Share, and COVID-19 Impact Analysis, By Dosage Form (Capsules, Tablets, and Others), By Indications (Angina Pectoris, Hypertension, and Others), By Distribution Channel (Retail Pharmacies, Online Pharmacies, Hospital Pharmacies, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 - 2033

Global Benidipine Market Insights Forecasts to 2033

• The Global Benidipine Market Size Was Estimated at USD 1.42 Billion in 2023
• The Market Size is Expected to Grow at a CAGR of around 5.43% from 2023 to 2033
• The Worldwide Benidipine Market Size is Expected to reach USD 2.41 Billion By 2033
• North America is predicted to Grow at the fastest CAGR throughout the projection period

The Global Benidipine Market Size is Predicted to Exceed USD 2.41 Billion By 2033, Growing at a CAGR of 5.43% from 2023 to 2033.

Market Overview

The benidipine market is a part of the pharmaceutical industry that deals with the development, production, and commercialization of benidipine, a calcium channel blocker used for the management of hypertension and ischemic heart diseases like angina pectoris. Benidipine, a calcium channel blocker, regulates blood pressure by relaxing blood vessels and reducing pressure, enabling the heart to pump more blood, normalizing blood pressure in high-pressure patients. This enhanced blood flow improves oxygen flow, preventing heart-related chest pain (angina) and enhancing overall health. The marketed products of benidipine are Bendicop-4, BENIDIN, Benitowa-Trio, etc.

The rising prevalence of hypertension escalates the need for benidipine medications for the treatment of hypertension, which leads to market growth. For instance, the World Heart Federation reported that hypertension affects 1.3 billion people globally, causing 10 million deaths annually. Low and middle-income countries are experiencing a growing prevalence of hypertension, causing a double burden of communicable and non-communicable diseases. Effective blood pressure management can save $100 billion annually in global healthcare costs.

Several government initiatives drive the growth of the benidipine market. For example, the Government of India launched the India Hypertension Control Initiative (IHCI) in November 2017 to reduce the prevalence of raised blood pressure by 25%. The initiative, led by the Indian government and state governments, was guided by WHO HEARTS, a technical package promoting comprehensive cardiovascular health strategies. The IHCI focuses on healthy lifestyle habits, evidence-based treatment protocols, access to essential medicines and technology, patient-centered care, team care, task-sharing, and monitoring systems. WHO India, as a member of the national Technical Advisory Group (TAG), directed the IHCI field implementation. With an estimated 20 crore adults with hypertension, only 2 crores have it under control. The government has adopted the "25 by 25" goal to reduce premature mortality due to non-communicable diseases (NCDs) by 25% by 2025.

Report Coverage

This research report categorizes the global benidipine market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyzes the key growth drivers, opportunities, and challenges influencing the global benidipine market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyzes their core competencies in each sub-segment of the global benidipine market.

Driving Factors

Increasing prevalence of angina pectoris:

Angina, a common symptom of ischemic heart disease, is a significant global health concern, with angina pectoris being its most common symptom. It doubles the risk of major cardiovascular events and causes 4.1 million deaths annually in Europe, with 82% of these deaths in people over 65. The incidence of angina is 1% in the Western male population aged 45-65. The prevalence of angina is expected to increase in the coming decade due to aging populations, life-prolonging therapies, better management of acute coronary syndromes, and the obesity epidemic. Therefore, the increasing prevalence of angina pectoris among populations accelerates the demand for calcium channel blockers such as benidipine drug resulting in market expansion.

Growing proportion of the geriatric population:

The benidipine market is being propelled by the geriatric population, as they are more prone to cardiovascular issues such as angina pectoris. The risk of hypertension and its complications rises because of changes in the cardiovascular system associated with aging. As a calcium channel blocker, benidipine is effective for hypertension and angina pectoris, making it a preferred option for elderly patients. The expanding geriatric population and rising life expectancy are augmenting the need for effective antihypertensive and anti-anginal medications, propelling the benidipine market.

Restraining Factors

The increasing procurement of the generic drugs, high cost of the branded benidipine drugs, stringent regulatory requirements, and repeated use of benidipine lead to cause adverse effects, which may impede the market growth.

Market Segmentation

The global benidipine market share is classified into dosage form, indications, and distribution channel.

• The tablets segment dominated the global benidipine market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period.

Based on the dosage form, the global benidipine market is categorized into capsules, tablets, and others. Among these, the tablets segment dominated the global benidipine market in 2023 and is anticipated to grow at a significant CAGR throughout the forecast period. The sector growth is attributed to the ease of administration, patient compliance, greater chemical and physical stability, enhanced physiological activity, precise dosing, greater efficacy, availability of novel drug delivery systems, and rapid onset of action.

• The hypertension segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.

Based on the indications, the global benidipine market is categorized into angina pectoris, hypertension, and others. Among these, the hypertension segment accounted for the largest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The segment growth is owing to the increasing prevalence of hypertension, the growing proportion of the geriatric population, sedentary lifestyles, obesity, and growing use of benidipine in the management of hypertension as it is more effective and lowers the blood pressure and reduces the vascular resistance.

• The hospital pharmacies accounted for a significant share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe.

Based on the distribution channel, the global benidipine market is categorized as retail pharmacies, online pharmacies, hospital pharmacies, and others. Among these, the hospital pharmacies accounted for a significant share in 2023 and is predicted to grow at a remarkable CAGR throughout the projected timeframe. The segment growth is ascribed to the availability of the wide stock of benidipine medications, improved medications adherence, counselling and dispensing medication facilities, and personalized medications.

Regional Segment Analysis of the Global Benidipine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia Pacific is anticipated to hold the largest share of the global benidipine market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of the global benidipine market over the predicted timeframe. This is driven by the high rates of hypertension and cardiovascular diseases, with a substantial patient population in countries like China and India, and rising healthcare expenditures are fueling market expansion. Government efforts to bolster healthcare infrastructure and promote the use of antihypertensive drugs are propelling market growth. Advances in drug delivery methods, including sustained-release formulations, are improving benidipine's effectiveness and adherence among patients. The growing elderly demographic in the Asia Pacific is increasing the need for effective treatments for hypertension and angina.

North America is anticipated to grow at the fastest CAGR throughout the projected timeframe. This is attributed to high hypertension prevalence and increasing awareness. The well-established healthcare system and demand for innovative treatments are driving growth. Key pharmaceutical companies and ongoing research contribute to the market's growth. The growing elderly population, more prone to cardiovascular conditions, and the rising incidence of hypertension and angina pectoris in North America also drive demand for effective treatments like calcium channel blockers like benidipine.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global benidipine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Lupin Limited
• Mylan N.V.
• Torrent Pharmaceuticals Ltd.
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Johnson and Johnson
• AbbVie Inc.
• Bayer AG
• Kyowa Kirin Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In January 2025, SSY Group Limited, a pharmaceutical company, received approval from the National Medical Products Administration of China for its Benidipine Hydrochloride, a treatment for primary hypertension and angina pectoris, to be marketed as a bulk drug. This move could enhance the company's product offerings and potentially strengthen its position in the market, benefiting shareholders and investors.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global benidipine market based on the below-mentioned segments:

Global Benidipine Market, By Dosage Form

• Capsules
• Tablets
• Others

Global Benidipine Market, By Indications

• Angina Pectoris
• Hypertension
• Others

Global Benidipine Market, By Distribution Channel

• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies
• Others

Global Benidipine Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa